Plus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Plus Therapeutics, Inc.
Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
- Generic Drugs
- Other Names / Subsidiaries
- Azaya Therapeutics, Inc.
- Cytori Therapeutics, Inc.